Abstract
Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of patients with pancreatic ductal adenocarcinoma (PDAC) with perc......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
